Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Nature Publishing Group
2013
|
| Online Access: | http://hdl.handle.net/20.500.11937/27277 |
| _version_ | 1848752218974453760 |
|---|---|
| author | Miles, D. de haas, S. Dirix, L. Romieu, G. Chan, Arlene Pivot, X. Tomczak, P. Provencher, L. Cortes, J. Delmar, P. Scherer, S. |
| author_facet | Miles, D. de haas, S. Dirix, L. Romieu, G. Chan, Arlene Pivot, X. Tomczak, P. Provencher, L. Cortes, J. Delmar, P. Scherer, S. |
| author_sort | Miles, D. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| first_indexed | 2025-11-14T08:05:08Z |
| format | Journal Article |
| id | curtin-20.500.11937-27277 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T08:05:08Z |
| publishDate | 2013 |
| publisher | Nature Publishing Group |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-272772018-12-14T00:57:07Z Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer Miles, D. de haas, S. Dirix, L. Romieu, G. Chan, Arlene Pivot, X. Tomczak, P. Provencher, L. Cortes, J. Delmar, P. Scherer, S. 2013 Journal Article http://hdl.handle.net/20.500.11937/27277 Nature Publishing Group restricted |
| spellingShingle | Miles, D. de haas, S. Dirix, L. Romieu, G. Chan, Arlene Pivot, X. Tomczak, P. Provencher, L. Cortes, J. Delmar, P. Scherer, S. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer |
| title | Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer |
| title_full | Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer |
| title_fullStr | Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer |
| title_full_unstemmed | Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer |
| title_short | Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer |
| title_sort | biomarker results from the avado phase 3 trial of first-line bevacizumab plus docetaxel for her2-negative metastatic breast cancer |
| url | http://hdl.handle.net/20.500.11937/27277 |